271 results on '"Nogova L"'
Search Results
2. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
3. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential
4. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
5. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
6. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
7. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort
8. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis
9. P13.03.A Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases
10. KS02.7.A Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors
11. 1308P Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations
12. The fading relevance of the quantity of brain metastases in patients with non-small cell lung cancer
13. Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases
14. RADIOMICS FOR THE NON-INVASIVE ASSESSMENT OF THE PDL-1 EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES
15. Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors
16. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
17. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics
18. The biological effect of small-scale ROS1 aberrations: An in silico analysis
19. Small-scale ROS1 aberrations: Functional impact and therapeutic potential
20. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort
21. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics
22. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
23. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
24. 1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
25. 1374P Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
26. 1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
27. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials
28. BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination: ID 422
29. Clinical and Molecular Characteristics of Non-Small Cell Lung Cancer Patients Harboring PIK3CA Mutations: ID 431
30. MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab: ID 439
31. TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.: ID 404
32. SORAVE: Sorafenib and everolimus for patients with solid tumors and with KRAS mutated NSCLC - results of a phase I study: ID 414
33. High throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathological routine diagnostics for a regional health care provider network: ID 112
34. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors
35. SO-10 Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
36. EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data
37. Small Cell Lung Cancer - Filling the gap between science and patients
38. KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup
39. FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
40. Ropivacain, ein vorteilhaftes Anästhetikum für die subkutane Infusionsanästhesie (SIA)
41. Feasibility of dynamic contrast-enhanced MRI (DCE-MRI) based angiogenesis biomarker assessment in advanced NSCLC treated with erlotinib and bevacizumab: V954
42. Fluoro-L-Thymidine (FLT) uptake in baseline positron emission tomography (PET) as a prognostic marker in patients with advanced non-small cell lung cancer (NSCLC) treated first-line with erlotinib: V957
43. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)
44. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study
45. A phase II clinical trial to evaluate the accuracy of [18]FDG/FLT-PET for early prediction of non-progression in patients with advanced Non Small Cell Lung Cancer (NSCLC) treated with erlotinib: V883
46. The Newly Developed Modified BEACOPP-Regimen (BACOPP) is Active and Feasible in Elderly Patientswith Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin StudyGroup (GHSG): V338
47. EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability
48. Salvage treatment for relapse after radiation therapy of early stage Hodgkinʼs disease - results of the German Hodgkinʼs Lymphoma Study Group (GHSG): P914
49. Lymphocyte-predominant Hodgkinʼs disease in clinical stage IA: Review of treatment options in three study generations of the German Hodgkin Study Group: P915
50. Autologous tandem transplantation with high-dose etoposide mobilized peripheral blood stem cells in patients with primary progressive Hodgkinʼs and aggressive non-Hodgkinʼs lymphoma: P899
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.